Quantcast

Latest Mantle cell lymphoma Stories

2010-12-06 14:01:56

Results with Estybon (ON 01910.Na) in Patients with myelodysplastic syndromes; ON 013105 cyclin D1 inhibitor active in models of mantle cell lymphoma NEWTOWN, PA and PRINCETON, NJ Dec. 3, 2010 / PRNewswire-FirstCall / Onconova Therapeutics announces its late-stage anticancer agent, Estybon® (ON 01910.Na), will be featured in three presentations at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 4-7, 2010. Principal investigators at four...

2010-12-05 07:00:00

ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-USNewswire/ -- The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable...

2010-12-01 00:04:00

EAST HANOVER, N.J., Dec. 1, 2010 /PRNewswire/ -- With more than 170 presentations focused on its marketed and pipeline compounds at key oncology medical congresses in December, Novartis continues to demonstrate progress of its innovative research and development efforts, collaboration with the scientific community and commitment to patients with cancer and rare diseases(1,2). The American Society of Hematology (ASH) annual meeting in Orlando, FL (December 4-7) will feature 30 oral...

2010-11-29 14:36:45

Researchers to present 12 oral and 28 poster sessions at the premier hematology research conference The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 "“ 6. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including...

2010-09-13 15:00:00

SUNNYVALE, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010. During the fiscal year ended June 30, 2010, total revenue recognized under GAAP was $9.3 million. No revenue was generated in the fiscal year ended June 30, 2009. The GAAP net loss reported for the fiscal year ended June 30, 2010 was $15.0 million, or $0.31 per share. This compares to a GAAP net loss...

2010-09-07 04:35:02

Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.Bendamustine is the subject of a license agreement concluded between the two companies in May 2009, in which SymBio granted Eisai the exclusive...

2010-07-12 14:11:11

Findings by the John Theurer Cancer Center may lead to more targeted clinical trials and therapies A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing. Blinatumomab is the first in a...

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable,...

2010-06-03 11:49:00

HACKENSACK, N.J., June 3 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related